Related Experiment Videos
Current status of the therapy of advanced renal carcinoma
Abstract:
A preclinical murine renal model system is available for evaluation of the effectiveness of therapeutic agents. Clinical review reveals that objective response rates to hormonal agents reported since 1971 have been substantially lower than those reported prior to 1971. Many chemotherapeutic agents have not been adequately evaluated clinically or with the experimental model. Vinblastine to date may be the most active single agent with a 25% objective response rate. At the present time, it is uncertain whether combination chemotherapy or hormonal chemotherapy add to response rates obtained with single agents. There is some evidence that immunotherapy may be of some adjuvant benefit and, thus may provide an additional avenue of investigation.
Insights
Evaluating therapeutic agents for renal models shows declining hormonal therapy effectiveness. Vinblastine is the most active single agent, but combination therapies and immunotherapy require further investigation for improved treatment outcomes.
Area of Science:
- Preclinical research
- Oncology
- Nephrology
Background:
- A preclinical murine renal model is available for therapeutic agent evaluation.
- Clinical data indicates a significant decline in objective response rates for hormonal agents since 1971.
- Many chemotherapeutic agents lack adequate clinical and experimental model evaluation.
Purpose of the Study:
- To assess the effectiveness of various therapeutic agents in a preclinical renal model.
- To review historical and current clinical response rates of hormonal agents.
- To identify promising chemotherapeutic agents and novel treatment strategies for renal disease.
Main Methods:
- Utilized a preclinical murine renal model system.
- Conducted a clinical review of objective response rates for hormonal agents reported since 1971.
- Evaluated the efficacy of single-agent chemotherapy, specifically Vinblastine.
- Assessed the potential benefits of combination chemotherapy, hormonal chemotherapy, and immunotherapy.
Main Results:
- Vinblastine demonstrated the highest objective response rate among single agents at 25%.
- Objective response rates for hormonal agents have decreased substantially compared to pre-1971 data.
- The efficacy of combination chemotherapy and hormonal chemotherapy in improving response rates remains uncertain.
- Immunotherapy shows potential as an adjuvant treatment, warranting further investigation.
Conclusions:
- The preclinical model provides a platform for evaluating renal therapeutic agents.
- There is a need for improved therapeutic strategies due to declining hormonal agent efficacy.
- Vinblastine shows promise as a single agent, but further research into combination therapies and immunotherapy is crucial for advancing renal cancer treatment.